Cipla targets new overseas markets via a China factory to bypass India's production limits, focusing on U.S. inhaler supplies.

• Chinese plant launched in 2024 to supply the U.S. with inhalation respule products, easing Indian capacity constraints.
• The company explores partnerships with 2-3 countries for Chinese-manufactured shipments, and discussions are ongoing for six to eight months.
• The facility produces 55 million inhaler units annually, addressing customer demands amid Indian production challenges.